A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

计划入组 28 人 · 首次发布于 2026 年 2 月 4 日

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

计划入组 45 人 · 首次发布于 2023 年 9 月 21 日

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

计划入组 92 人 · 首次发布于 2021 年 5 月 7 日

NS-229

RAGE-229

RD-229

GlobeImmune, Inc.

United States

University of Santiago de Compostela

Spain

Viridian Metals Inc

United States

Nuclear Waste from Manhattan Project Transformed into Breakthrough Cancer Treatment at Oak Ridge

New Oak Ridge Lab Accelerates Actinium-225 Supply for Next-Generation Cancer Therapies

TerraPower Isotopes Commercially Produces Actinium-225 for Targeted Cancer Therapies